WO2014046474A3 - 메트포민을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물 - Google Patents

메트포민을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물 Download PDF

Info

Publication number
WO2014046474A3
WO2014046474A3 PCT/KR2013/008428 KR2013008428W WO2014046474A3 WO 2014046474 A3 WO2014046474 A3 WO 2014046474A3 KR 2013008428 W KR2013008428 W KR 2013008428W WO 2014046474 A3 WO2014046474 A3 WO 2014046474A3
Authority
WO
WIPO (PCT)
Prior art keywords
metformin
preventing
inflammatory bowel
bowel disease
composition
Prior art date
Application number
PCT/KR2013/008428
Other languages
English (en)
French (fr)
Other versions
WO2014046474A2 (ko
Inventor
조미라
이선영
양은지
손혜진
김은경
유준걸
Original Assignee
가톨릭대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가톨릭대학교 산학협력단 filed Critical 가톨릭대학교 산학협력단
Priority claimed from KR1020130111679A external-priority patent/KR101501375B1/ko
Publication of WO2014046474A2 publication Critical patent/WO2014046474A2/ko
Publication of WO2014046474A3 publication Critical patent/WO2014046474A3/ko
Priority to US14/663,235 priority Critical patent/US9700531B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 메트포민을 유효성분으로 포함하는 염증성 장질환의 예방 또는 치료용 조성물에 관한 것으로, 본 발명에 따른 메트포민(metformin) 화합물 또는 메트포민과 이타너셉트(etanercept, 제품명: 엔브렐)의 복합체는 소장의 두께 및 대장의 길이를 정상과 같이 유지 시키는 효과가 우수하고, IL-17 및 TNF-a의 활성을 억제 또는 감소시키는 효과가 우수하며, IFNr의 활성을 촉진 또는 증가시키는 효과가 우수하여 염증성 장질환 포함 자가면역질환을 예방 또는 치료할 수 있는 약학적 조성물로 유용하게 사용할 수 있다.
PCT/KR2013/008428 2012-09-21 2013-09-17 메트포민을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물 WO2014046474A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/663,235 US9700531B2 (en) 2012-09-21 2015-03-19 Composition comprising metformin as active ingredient for preventing or treating inflammatory bowel disease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2012-0104969 2012-09-21
KR20120104969 2012-09-21
KR10-2013-0111679 2013-09-17
KR1020130111679A KR101501375B1 (ko) 2012-09-21 2013-09-17 메트포민을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/663,235 Continuation-In-Part US9700531B2 (en) 2012-09-21 2015-03-19 Composition comprising metformin as active ingredient for preventing or treating inflammatory bowel disease

Publications (2)

Publication Number Publication Date
WO2014046474A2 WO2014046474A2 (ko) 2014-03-27
WO2014046474A3 true WO2014046474A3 (ko) 2014-05-22

Family

ID=50342047

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2013/008428 WO2014046474A2 (ko) 2012-09-21 2013-09-17 메트포민을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물

Country Status (1)

Country Link
WO (1) WO2014046474A2 (ko)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142993A1 (en) * 2000-10-12 2002-10-03 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of bicyclic compounds
US20090143442A1 (en) * 2006-03-16 2009-06-04 Colca Gerard R Thiazolidinedione analogues
WO2011056590A1 (en) * 2009-10-26 2011-05-12 Prometheus Laboratories Inc. Assays for the detection of anti-tnf drugs and autoantibodies
US20110294852A1 (en) * 2006-09-29 2011-12-01 Novo Nordisk A/S Pharmaceutical Formulation Comprising Metformin and Repaglinide
WO2013079721A1 (en) * 2011-12-01 2013-06-06 Bergen Teknologioverføring As Marker and method for diagnosing diarrhea syndrome

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142993A1 (en) * 2000-10-12 2002-10-03 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of bicyclic compounds
US20090143442A1 (en) * 2006-03-16 2009-06-04 Colca Gerard R Thiazolidinedione analogues
US20110294852A1 (en) * 2006-09-29 2011-12-01 Novo Nordisk A/S Pharmaceutical Formulation Comprising Metformin and Repaglinide
WO2011056590A1 (en) * 2009-10-26 2011-05-12 Prometheus Laboratories Inc. Assays for the detection of anti-tnf drugs and autoantibodies
WO2013079721A1 (en) * 2011-12-01 2013-06-06 Bergen Teknologioverføring As Marker and method for diagnosing diarrhea syndrome

Also Published As

Publication number Publication date
WO2014046474A2 (ko) 2014-03-27

Similar Documents

Publication Publication Date Title
IN2012DN02805A (ko)
WO2014097151A3 (en) Autotaxin inhibitors
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
MX2012012438A (es) Formulaciones farmaceuticas que comprenden pioglitazona y linagliptina.
MX2015005174A (es) Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo.
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
WO2015077503A8 (en) Autotaxin inhibitor compounds
UA109661C2 (uk) Фармацевтична композиція співкристалів трамадолу і коксибів
WO2009121945A3 (en) Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
EA201391315A1 (ru) Гуанидиновое соединение
WO2012065963A3 (en) Antiviral condensed heterocyclic compounds
MX2010014057A (es) Compuestos de piridina.
MX340188B (es) Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
MX340985B (es) Compuestos de n-heteroarilo.
MY195343A (en) A Novel Phtalazinone Derivatives and Manufacturing Process Thereof
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
WO2013169631A3 (en) Wnt protein signalling inhibitors
WO2011149288A2 (ko) 복수의 타이로신 카이네이즈에 대한 저해 활성을 가지는 항염증 화합물 및 이를 포함하는 약학적 조성물
WO2011088160A3 (en) Novel cyp17 inhibitors
WO2008146172A3 (en) Compounds with antiparasitic activity, applications thereof to the treatment of infectious diseases caused by apicomplexans
WO2007098967A3 (en) Imidazole compounds having pharmaceutical activity towards the sigma receptor
WO2011027258A3 (en) Scented capsules
WO2011014520A3 (en) Compounds and compositions as modulators of gpr119 activity
WO2010090611A3 (en) Taste and odor masked pharmaceutical compositions with high bioavailability

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13838852

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13838852

Country of ref document: EP

Kind code of ref document: A2